Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

If you wouldn't invest in flu vaccines, then you shouldn't view the ongoing coronavirus outbreak as a noteworthy investing opportunity.

Coronavirus Uncertainty Spreads, but Investors Should Remain Calm

Allied Healthcare Products

Alpha Pro Tech

BioCryst Pharmaceuticals

Cerus

Co-Diagnostics

Dyadic International Inc., DE

Lakeland Industries

NanoViricides

Novavax

Vir Biotechnology

Monday morning brought a huge sell-off in the market as more and more people are concerned about the growing impact of this new coronavirus.

12 Stocks Surging That Could Help Treat or Fight Coronavirus

Shares of a handful of vaccine makers, diagnostics companies and manufacturers of medical supplies, like masks, rallied again in premarket trading on Monday over growing public concern about the new coronavirus. This includes Co-Diagnostics Inc.

Vaccine, diagnostics stocks rise again on spreading coronavirus

Investors are bidding up these biotechs in response to the health threat.

2 Stocks That Could Skyrocket Over the Chinese Coronavirus Threat

Gilead Sciences

But it's important to separate the current panic from the real potential for these biotechs.

5 Biotech Stocks to Watch With the Coronavirus Scare

The company is developing a vaccine against the 2019-nCoV coronavirus.

Here's Why  Inovio Pharmaceuticals Jumped Higher Today

American Airlines

Delta Air Lines

Estee Lauder

LVMH Moet Hennessy Louis Vuitton

Royal Caribbean Cruises

United Continental Hlds

So far, 18 fatalities and more than 600 are affected by coronavirus in China and the virus is spreading across the boundary, spooking investors.

Coronavirus Spooks Global Markets: Winners and Losers

Several public and private organizations are coming forward to develop vaccines for the new coronavirus by funding developmental programs.

CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs

Inovio was awarded a $9 million grant to develop a vaccine against the emerging coronavirus threat.

Why Inovio Pharmaceuticals Stock Bolted Higher Today

Aethlon Medical

AstraZeneca

Cleveland BioLabs

Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.

13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak

Alphatec Hlds

BioDelivery Sciences

BioXcel Therapeutics

Amicus Therapeutics

Geron

Insmed

When searching for massive gains that can be achieved in the blink of an eye, look no further than healthcare stocks. Here are seven that stand out according to the Street.

7 Healthcare Stocks With 100% Street Support

Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.

Implied Volatility Surging for Inovio (INO) Stock Options

Shares of several vaccine makers were on the rise Tuesday following reports of a spreading coronavirus outbreak in Asia.

4 Vaccine Stocks Making Big Moves Amid Coronavirus Outbreak

A New Decade And A Fresh Start For Inovio

Inovio Pharmaceuticals: Roth Capital $13 Target Evaluated

An analyst likes the biotech, and investors are following suit.

Here's Why Inovio Pharmaceuticals (INO) Jumped Higher Today

Inovio (INO) reported earnings 30 days ago. What's next for the stock?

Inovio (INO) Up 14.3% Since Last Earnings Report: Can It Continue?

Why are analysts so bullish on this small-cap biotech stock, and are they justified?

Is Inovio Pharmaceuticals a Buy? (INO)

These two pharma micro-caps are approaching climactic phase 3 trials.

Better Buy: Novavax vs. Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim presents at Stifel 2019 Healthcare Brokers Conference (Transcript)

Inovio's (INO) loss in the third quarter meets estimates while revenues miss the same. Lead vaccine candidate VGX-3100 is in focus.

Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2019 Results Conference Call November 12, 2019 4:30 PM ET

Inovio Pharmaceuticals, Inc. (INO) CEO Dr. J. Joseph Kim on Q3 2019 Results - Earnings Call Transcript

Inovio (INO) delivered earnings and revenue surprises of 0.00% and -68.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Inovio Pharmaceuticals (INO) Reports Q3 Loss, Misses Revenue Estimates

Inovio (INO) Down 16.1% Since Last Earnings Report: Can It Rebound?

Inovio (INO) stops the development of INO-5401 for advanced bladder cancer, and cuts workforce by 28% and annual burn rate by 25% as part of the restructuring process.

Inovio (INO) Down More Than 30% in 3 Months: Here's Why

News for Inovio Pharmaceuticals Stock (INO)